The June 29 marijuana rescheduling hearing: what it can decide, what it cannot, and why the participant list is now locked

The April 22, 2026 order that moved FDA-approved and state-licensed medical marijuana to Schedule III was, by design, only half a decision. It rescheduled two narrow categories and deferred the larger question (whether all marijuana should follow) to a formal administrative hearing. That hearing begins June 29, 2026. As of this week, one thing about it is settled: the deadline to request participation was May 28, so the roster of who gets to put evidence in front of the administrative-law judge is now fixed.

This is a preview of the proceeding, written before it begins. It does not predict the outcome. No one credibly can. It maps what the hearing is structurally able to decide, what it cannot touch no matter how it goes, and the constitutional problem that several observers think will follow any result into court. For the retrospective companion on what the April order already did, see where federal rescheduling actually stands.

The logistics, now fixed

The hearing convenes June 29, 2026 at 9:00 a.m. ET at the DEA Hearing Facility, 700 Army Navy Drive, Arlington, Virginia. Per the Federal Register hearing notice, it is expedited: it recesses July 3, reconvenes July 6, and must conclude no later than July 15. That is a compressed evidentiary window for a question this large: roughly two working weeks of hearing time.

The participation mechanics are the timely part. Interested persons who wanted to participate had to file written notice on or before May 28, 2026. That date has passed. The practical consequence: the set of parties who will be heard is now locked. That set includes state medical-cannabis trade associations, patient-advocacy organizations, industry coalitions, and any opposing participants. Parties who missed the deadline are limited to whatever public-comment or amicus avenues remain, not live participation in the evidentiary record. Anyone tracking the proceeding should now be watching the participant list and the pre-hearing motions, not waiting for a window to join.

As of this writing the presiding administrative-law judge had not been formally designated, and the detailed evidentiary schedule was still being set. Those are the next procedural shoes to drop before June 29.

What the hearing can decide

The hearing's stated purpose is singular: receive evidence on whether all forms of marijuana should be downscheduled from Schedule I to Schedule III through the formal rulemaking process. Structurally, it can produce:

• A recommended decision from the ALJ, based on the hearing record, on whether the full marijuana category meets the Controlled Substances Act criteria for Schedule III rather than Schedule I.
• An evidentiary record that the DOJ can use to support a second, broader final order. Such an order would extend Schedule III treatment beyond the April 22 medical-only categories to the rest of the cannabis category.
• A litigated foundation that a future administration could either ratify or move to unwind, depending on what the record contains.

If the proceeding supports broader rescheduling and the DOJ acts on it, the headline effect would be to extend to the wider cannabis category the same federal changes the April order brought to state medical operators: removal of the Section 280E federal-tax penalty, a lower barrier to research access, and a DEA-registration pathway. The Congressional Research Service analysis (LSB11105) lays out the scope of what a scheduling change does and does not reach.

What the hearing cannot do, no matter the result

This is the part most worth being clear about, because rescheduling is routinely confused with legalization. A favorable hearing record and a subsequent broader Schedule III order still would not:

• Legalize cannabis federally. Schedule III is a controlled-substance classification, not legalization. Marijuana would remain a regulated controlled substance, simply in a lower tier.
• Authorize interstate commerce. Moving cannabis across state lines would remain federally prohibited regardless of schedule.
• Create insurance coverage for patients. Coverage tracks FDA approval for specific indications, not scheduling. Outside Epidiolex's narrow labeling, medical cannabis would remain out-of-pocket.
• Let physicians "prescribe" state-program cannabis. State programs operate through certification and recommendation, not federal controlled-substance prescribing. A scheduling change does not convert a state medical card into a federal prescription.
• Provide federal employment, security-clearance, or DOT protections. Those rules are independent of schedule; see federal employment and medical cannabis for the operational detail.
• Preempt or modify state medical-cannabis statutes. Qualifying conditions, possession limits, and program rules remain entirely a matter of state law.

For a patient holding a state medical card, in other words, even a maximalist outcome of the June 29 hearing changes very little about the day-to-day experience. The changes rescheduling produces are concentrated at the operator, research, and federal-tax levels, not at the dispensary counter.

The constitutional cloud

The structural risk hanging over the proceeding is unusual: the Department of Justice has admitted in federal court that the DEA's administrative-law-judge structure (specifically the dual-layer for-cause removal protection for these ALJs) is unconstitutional under the Supreme Court's reasoning in Free Enterprise Fund v. PCAOB (2010). The same department that owns the rescheduling proceeding is on record describing the officers who run it as constitutionally infirm.

That creates a vulnerability the Moritz College of Law rescheduling tracker and numerous practitioners have flagged: any final rulemaking output of the June 29 hearing is exposed to a constitutional challenge the agency itself has conceded. Whether courts treat that defect as fatal or curable is genuinely unsettled. There is no Supreme Court precedent directly on point for an ALJ proceeding the executive branch has already admitted is unconstitutionally structured. Expect at least one such challenge filed within weeks of any broader order.

What to watch between now and June 29

Three things will shape the hearing before it opens:

1. The ALJ designation. Who the Attorney General names to preside, and that judge's prior record, will color how the evidentiary record develops in a two-week window.
2. The locked participant list and pre-hearing motions. With participation requests closed as of May 28, the live action moves to motions to intervene, motions on scope, and the evidentiary schedule. The composition of participants is a strong early signal of how contested the record will be.
3. Any pre-emptive constitutional filing. A challenge to the ALJ structure could land before the hearing even convenes, which would test whether the proceeding can produce a durable result at all.

The honest summary for late May 2026: the April 22 order resolved the easy half of rescheduling, the June 29 hearing is the formal vehicle for the hard half, the roster of who will be heard is now set, and the most likely sequel to any broad result is litigation rather than finality.

Related reading

• Where federal marijuana rescheduling actually stands: the retrospective on what the April 22 order did and did not change
• Federal employment and medical cannabis: why scheduling does not touch workplace and clearance rules
• 2026 state legislative bills tracker: state-level cannabis legislation moving in parallel
• How to get a medical marijuana card: the state process that rescheduling leaves intact

[Last reviewed 2026-05-31. This is informational only, not medical or legal advice. This article previews a pending administrative proceeding; outcomes, dates, and participants are subject to change.]